과호산구증가증을 동반한 Sézary 증후군
Hypereosinophilia secondary to Sézary syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma characterized by the presence of erythroderma covering at least 80% of the body-surface area, lymphadenopathy, and the presence of clonally related neoplastic T cells with cerebriform nuclei (Sézary cells) in the blood, skin, and lymph nodes. Hypereosinophilia can be caused by hematologic malignancy with clonal abnormality, which is often associated with Sézary syndrome. Sézary syndrome has rarely been reported in Korea. However, hypereosinophilia in the Sézary syndrome has not been reported in Korea. Here, we report a case of 75-year-old man with hypereosinophila, erythroderma, and cutaneous T-cell lymphoma which was finally diagnosed as Sézary syndrome.
Abstract
The Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma characterized by the presence of erythroderma covering at least 80% of the body-surface area, lymphadenopathy, and the presence of clonally related neoplastic T cells with cerebriform nuclei (Sézary cells) in the blood, skin, and lymph nodes. Hypereosinophilia can be caused by hematologic malignancy with clonal abnormality, which is often associated with Sézary syndrome. Sézary syndrome has rarely been reported in Korea. However, hypereosinophilia in the Sézary syndrome has not been reported in Korea. Here, we report a case of 75-year-old man with hypereosinophila, erythroderma, and cutaneous T-cell lymphoma which was finally diagnosed as Sézary syndrome.
참고문헌 (17)
- Sézary A, "Erythrodermic avec presence de cellules monstreuses dans le derme et dans le sang circulant", Bull Soc Fr Dermatol Syph, 45, pp.256~260 (1938)
- Taswell HF, "Sézary syndrome-a malignant reticulemic erythroderma", JAMA, 117, pp.465~472 (1961)
- Weinstock MA, "Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides", Cancer, 62, pp.1658~1661 (1988)
- Rothenberg ME, "Eosinophilia", N Engl J Med, 338, pp.1592~1600 (1998)
- Valent P, "Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes", J Allergy Clin Immunol, 130, pp.607~612 (2012)
- Borish L, "Sézary syndrome with elevated serum IgE and hypereosinophilia : role of dysregulated cytokine production", J Allergy Clin Immunol, 92, pp.123~131 (1993)
- Davarifar A, "Profound hypereosin ophilia secondary to sezary syndrome", Blood, 126, pp.5053~ (2015)
- Carter JB, "Case : a 53-year-old woman with erythroderma, pruritus, and lymphadenopathy", N Engl J Med, 369, pp.559~569 (2013)
- Vonderhein EC, "ISCL update on erythrodermic cutaneous T-cell lymphoma : report of the International Society for Cutaneous Lymphomas", J Am Acad Dermatol, 46, pp.95~106 (2002)
- Hoppe RT, "Mycosis fungoides and the Sézary syndrome : pathology, staging, and treatment", Curr Probl Cancer, 14, pp.293~371 (1990)
- Todenhofer T, "Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma", BMC Urol, 12, pp.7~ (2012)
- Sanderson CJ, "Interleukin-5, eosinophils, and disease", Blood, 79, pp.3101~3109 (1992)
- Collins PD, "Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo", J Exp Med, 182, pp.1169~1174 (1995)
- 박찬선, "과호산구증가증 분류와 치료의 최신지견", Allergy Asthma & Respiratory Disease, 3(6), pp.387~395 (2015), 대한 소아알레르기 호흡기학회[DOI]
- Whittaker S, "How I treat mycosis fungoides and Sézary syndrome", Blood, 127, pp.3142~3153 (2016)
- Lundin J, "Phase 2 study of alemtuzumab(anti-CD52 monoclonal antibody)in patients with advanced mycosis fungoides", Sézary syndrome, 2003, pp.101, 4267~4272
- Sausville EA, "Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome : definition of three distinctive prognostic groups", Ann Intern Med, 109, pp.372~382 (1988)